Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,296 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Immune System and Related Disorders Clear all
Completed Phase 4 Interventional Results available

The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma

NCT04400318
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Westminster, California • Kansas City, Kansas • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIV

NCT00001049
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 3 Months
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
45
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects

NCT00000740
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Sitamaquine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
2
States / cities
Indianapolis, Indiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma

NCT02969408
View directory record Official record
Conditions
Asthma
Interventions
Albuterol Sulfate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
44
States / cities
Litchfield Park, Arizona • Bakersfield, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional

Efficacy of Group Intervention to Reduce Stress Symptoms

NCT00611338
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, HIV Infections
Interventions
HIV Skills-based Prevention
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 11, 2026, 8:23 AM EDT
Not listed Not applicable Interventional

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

NCT00006055
View directory record Official record
Conditions
Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis, Churg-Strauss Syndrome, Hypersensitivity Vasculitis, Wegener's Granulomatosis, Systemic Lupus Erythematosus, Giant Cell Arteritis, Pure Red Cell Aplasia, Juvenile Rheumatoid Arthritis, Polyarteritis Nodosa, Autoimmune Thrombocytopenic Purpura, Takayasu Arteritis
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, filgrastim, methylprednisolone, prednisone, Autologous Peripheral Blood Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Fairview University Medical Center
Other
Eligibility
1 Year to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis

NCT00003368
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
45
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 11, 2026, 8:23 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Immune Regulation in Ulcerative Colitis or Crohn s Disease

NCT00001184
View directory record Official record
Conditions
Inflammatory Bowel Disease, Ulcerative Colitis, Chrohn's Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1998
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional

Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection

NCT00000955
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Tuberculin Purified Protein Derivative
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
14
States / cities
New Haven, Connecticut • Wilmington, Delaware • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2 Interventional

Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants

NCT00130819
View directory record Official record
Conditions
Opiate Dependence, HIV Seropositivity, HIV Infections
Interventions
Clinic-based substance abuse treatment with buprenorphine, Case management and referred substance abuse treatment
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Brief Negotiation Interview Chatbot to Improve Buprenorphine Engagement Among Justice-Involved Individuals

NCT04982627
View directory record Official record
Conditions
Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Criminal Behavior
Interventions
BNI Chatbot, OUD Education & Treatment Resources
Behavioral
Lead sponsor
Center for Progressive Recovery, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 11, 2026, 8:23 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Transgender Cohort Study of Gender Affirmation and HIV-related Health

NCT03595956
View directory record Official record
Conditions
HIV/AIDS, STI, Gender Dysphoria, Transsexualism, Gender Identity, Depression, Anxiety
Interventions
Medical gender affirmation
Other
Lead sponsor
Fenway Community Health
Other
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Sep 11, 2026, 8:23 AM EDT
Recruiting Not applicable Interventional

rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder

NCT05974202
View directory record Official record
Conditions
Cocaine Use, Cocaine Dependence, Cocaine Use Disorder, Cocaine Use Disorder, Moderate, Cocaine Use Disorder, Severe
Interventions
Active H7-coil repetitive transcranial magnetic stimulation (rTMS), Sham H7-coil repetitive transcranial magnetic stimulation (rTMS)
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
22 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional

Mindfulness - Based Stress Reduction and the Relationship on Inflammation in Autoimmune Hepatitis

NCT02950077
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
mindfulness based stress reduction
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Sep 11, 2026, 8:23 AM EDT
Terminated Phase 1 Interventional

Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain

NCT01846429
View directory record Official record
Conditions
Tumor, Cancer, Pain, Malignant Solid Tumor, Unresectable Malignant Neoplasm, Hematologic Malignancy, Multiple Myeloma, Lymphoma, Neoplasm Metastasis
Interventions
Sodium Bicarbonate
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Sep 11, 2026, 8:23 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department

NCT07726069
View directory record Official record
Conditions
Cannabinoid Hyperemesis Syndrome
Interventions
Haloperidol
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Human Monoclonal Antibody, F105, in the Treatment of HIV

NCT00001105
View directory record Official record
Conditions
HIV Infections
Interventions
F105 Monoclonal Antibody (Human)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection

NCT00000812
View directory record Official record
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
6
States / cities
Aurora, Colorado • Minneapolis, Minnesota • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 1 Interventional

Open Label Phase I Study To Evaluate the Safety of Combination Therapy With AZT and Interferon-Beta in Patients With AIDS Related Kaposi's Sarcoma

NCT00000695
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Interferon beta-1b, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional

Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component

NCT00000665
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium, Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2011 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT

NCT00002436
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine, Zidovudine, Zalcitabine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 11, 2026, 8:23 AM EDT
Recruiting Not applicable Interventional

Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study

NCT04949464
View directory record Official record
Conditions
HIV Infection, Tobacco-Related Carcinoma
Interventions
Computed Tomography, Smoking Cessation Intervention
Procedure · Behavioral
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
45 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
La Jolla, California • Washington D.C., District of Columbia • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 11, 2026, 8:23 AM EDT
Terminated No phase listed Observational

Draining PLN and Synovial Inflammation in RA Knee Joints Pre and Post Anti-TNF or B Cell Depletion Therapy

NCT01083563
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Sep 11, 2026, 8:23 AM EDT
Completed No phase listed Observational

The CORE Buprenorphine Project - An HIV Primary Care Program Demonstration

NCT00227357
View directory record Official record
Conditions
HIV Infections, AIDS, Opiate Dependence, Post-Traumatic Stress Disorders
Interventions
On-site - buprenorphine/naloxone (Suboxone), Off-site - methadone or no agonist
Drug
Lead sponsor
Ruth M. Rothstein CORE Center
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2010 · Synced Sep 11, 2026, 8:23 AM EDT